IR-News

AUSSENDER



Medigene AG
Ansprechpartner: Medigene PR/IR
Tel.: +49 89 2000 33 3301
E-Mail: investor@medigene.com

WEITERE IR-NEWS

pta20180824006
Business news for the stock market

Medigene AG: Medigene participates at five upcoming conferences


Planegg (pta006/24.08.2018/07:30) - Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at the following upcoming investor and scientific conferences:

Annual Neoantigen Targeted Therapies Meeting
as part of the Annual Immuno-Oncology Summit
Date: 30 - 31 August 2018
Location: Boston, USA
Dr Slavoljub Milosevic, Head of Technology Innovation of Medigene AG, will hold a presentation titled "Rapid High-Throughput Functional Selection of Neoantigens and Assessment of Their Safety" on 31 August at 10:05 am.

EF Herbstkonferenz (Initiator: DVFA)
Date: 3 - 4 September 2018
Location: Frankfurt, Germany
Dr Thomas Taapken, CFO of Medigene AG, will hold a company presentation on 3 September at 9:30 am

CAR-TCR Summit 2018
Date: 4 - 7 September 2018
Location: Boston, USA
Prof. Dolores Schendel, CEO and CSO of Medigene AG, is invited to hold a presentation titled "Moving from CAR-T to TCR-T Success" on 5 September at 3 pm.

RW Baird Healthcare Conference
Date: 5 - 6 September 2018
Location: New York, USA
Dr Thomas Taapken, CFO of Medigene AG, is invited to hold a company presentation on 6 September at 12:50 pm.

International Conference on Lymphocyte Engineering (ICLE 2018)
Date 13 - 15 September 2018
Location: Madrid, Spain

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit http://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)
emitter: Medigene AG
Lochhamer Straße 11
82152 Planegg
Germany
contact person: Medigene PR/IR
phone: +49 89 2000 33 3301
e-mail: investor@medigene.com
website: www.medigene.de
stock exchanges: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
ISIN(s): DE000A1X3W00
|
|
98.207 Abonnenten
|
172.891 Meldungen
|
69.563 Pressefotos

BUSINESS

23.07.2019 - 16:30 | Pöhacker Sabine - comm:unications
23.07.2019 - 12:30 | pressetext.redaktion
23.07.2019 - 12:00 | IfM - Institut für Management G.m.b.H
23.07.2019 - 11:05 | IG Windkraft
23.07.2019 - 09:30 | TÜV AUSTRIA Sila Kalite
Top